试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
编号:NCT03853317登记状态:提前终止企业 / 申办者:ImmunityBio, Inc.
药物 / 成分:Avelumab、N-803、haNK™
登记的停止原因(原文):Not meeting recruitment goal
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
编号:NCT03866239登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Obinutuzumab、Atezolizumab、Cibisatamab、Tocilizumab
登记的停止原因(原文):The Sponsor terminated the study because development of cibisatamab has been discontinued.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
Effects of Dietary Conditions on Drug Response
编号:NCT04315961登记状态:提前终止企业 / 申办者:Johns Hopkins University
药物 / 成分:Blinded drug dose conditions
登记的停止原因(原文):Unable to recruit participants.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
编号:NCT04583488登记状态:提前终止企业 / 申办者:Johns Hopkins University
药物 / 成分:Intraperitoneal docetaxel
登记的停止原因(原文):PI left institution
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
The Potential of Camostat in COVID-19
编号:NCT04625114登记状态:提前终止企业 / 申办者:University Hospital, Ghent
药物 / 成分:Camostat、Placebo、Camostat、Placebo
登记的停止原因(原文):Interim analyses did not show evidence that camostat mesylate under the present conditions (300 mg three times daily for five or 10 consecutive days, fasted state) was effective as an antiviral drug against early phase SARS-CoV-2 disease.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
编号:NCT04915352登记状态:提前终止企业 / 申办者:Centre Hospitalier Régional Metz-Thionville
药物 / 成分:Nasal provocation test - 725 Dermatophagoides Pteronyssinus、Negative control
登记的停止原因(原文):The study is terminated because the product (nasal provocation test) is out of stock.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
编号:NCT05084859登记状态:提前终止企业 / 申办者:Biosplice Therapeutics, Inc.
药物 / 成分:SM08502、Abiraterone、Prednisone、Docetaxel
登记的停止原因(原文):Study was terminated due business reasons by Sponsor.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
Testosterone & Tamoxifen Trial
编号:NCT05156606登记状态:提前终止企业 / 申办者:University Medical Center Groningen
药物 / 成分:AndroGel
登记的停止原因(原文):Five patients were included; it did not succeed in recruiting the target number of 6 patients. This is as a result of the rarity of this disease in men.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke
编号:NCT05240560登记状态:提前终止企业 / 申办者:Bioprojet
药物 / 成分:BP1.3656
登记的停止原因(原文):Lack of recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
编号:NCT05352542登记状态:提前终止企业 / 申办者:jianming xu
药物 / 成分:GPC3 Targeting CART Cells
登记的停止原因(原文):achieve the proof of concept
查看官方原始记录 ↗